Investors and analysts can join the session by dialing 1-800-836-8184 from North America or 1-646-357-8785 for international access. The company recommends that participants dial in 10 to 15 minutes before the scheduled start to ensure a timely connection. Additional details regarding the event are available through the investor relations portal at investors.precigen.com.

Precigen currently focuses on commercializing precision medicines, including its therapy for recurrent respiratory papillomatosis, PAPZIMEOS. The upcoming briefing comes as the company continues to navigate its core therapeutic pipeline across immuno-oncology, autoimmune, and infectious disease sectors, with management maintaining a focus on reaching cash flow break-even.